Testing effectiveness (Phase 2)Study completedNCT00290498
What this trial is testing
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 67